glp 1 gastroparesis How Dangerous Is Gastroparesis? Gastrointestinal manifestations of diabetes mellitus

Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

To schedule your free consultation near Midtown in NYC and to learn more about compounded GLP-1 medications, please call Just Melt Med Spa today at 212-447-1155

The available research suggests that the most important nutritional side effects of GLP-1 drugs include inadequate protein intake, loss of lean muscle mass, vitamin D deficiency, B-vitamin problems including thiamine, iron depletion, anemia, and low intake of key minerals like calcium, magnesium, and potassium

The FDA issued warning letters in March 2026 (sourced: FDA.gov press announcement, March 3, 2026) targeting companies that obscured this distinction

9 All-cause mortality reduction In a systematic review and meta-analysis of cardiovascular outcome trials (ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND, PIONEER 6), use of GLP-1RAs reduced all-cause mortality by 12% compared with placebo (hazard ratio [HR] 0.88